European Parliament vote on the revision of the EU’s legislative framework on F-gas: climate targets need innovative solutions
03 April 2023
In 2022 Chiesi Group has been confirmed as the 1st Italian pharmaceutical company for the number of patents filed
28 March 2023
What does it mean to be a B Corp? Chiesi's choice for a sustainable future
01 March 2023
Rare Disease Day
28 February 2023
The Chiesi Group and gender equality: a concrete achievement now certified by Bureau Veritas
10 February 2023
Chiesi Group stands in solidarity with the people of #Turkiye and #Syria
09 February 2023
The Alphabet of Sustainability
01 February 2023
Discovering ESG Criterias (Environmental, Social and Governance), the Chiesi Group's committment
17 January 2023
From cells to packaging
29 December 2022
Chiesi’s new interim CEO
16 December 2022
Energize Programme: a shared commitment to accelerate the adoption of renewable energy in the pharmaceutical sector
17 November 2022
“Vendor Day”: the role of Chiesi Group’s Value Chain in shaping the future
16 November 2022
Chiesi recognized by Biden Administration for its support and commitment to greater resilience in the fight against climate change
14 November 2022
Fostering innovation for rare diseases in Europe: Chiesi supports the RDR Challenges Call
27 October 2022
Giacomo Chiesi awarded by PharmaVoice100
09 September 2022
A new EU proposal to protect people and planet by reducing F-gases
01 August 2022
Chiesi Group joins Biden Administration pledge to decarbonize healthcare sector
06 July 2022
CO2alizione Italia: not just a declaration of intent
23 June 2022
The Art of Healing
08 June 2022
Dear colleagues, it's showtime!
31 May 2022
A musical manifesto to rewrite the future
23 May 2022
Innovating for the health of the planet and people, starting from the little things
20 May 2022
New record for Chiesi Group: in 2021 it’s confirmed top Italian pharmaceutical company for number of patents filed
28 April 2022
The way towards a sustainable and resilient healthcare
24 January 2022
Why biotech world needs new plants
17 December 2021
World Prematurity Day: Chiesi’s commitment for the premature babies
30 November 2021
Partners and suppliers protagonists of Chiesi Vendor Day 2021
29 November 2021
“Helping the World to Breathe” - Chiesi Group among the protagonist of the ATS docuseries
22 November 2021
Head of Chiesi Global Rare Diseases Recognized at RARE Champions of Hope Awards 2021
18 November 2021
Chiesi wins the Diversity Leaders Award for the third consecutive year
18 November 2021
The President Alberto Chiesi guest at the Farmindustria roadshow
16 November 2021
Chiesi supports the São Paulo Declaration on Planetary Health
27 October 2021
We ACT Day 2021: this year’s edition of Chiesi’s event for a sustainable future
23 September 2021
We’re all aware of the climate crisis, but we’re not talking about its impact on respiratory health.
08 September 2021
Chiesi Group is among "Sustainability Leaders 2021" companies in Italy
29 April 2021
D&I Policy: a further demonstration of Chiesi's commitment
20 April 2021
New record for the Chiesi Group, which is confirmed top Italian pharmaceutical company for number of patents filed
23 March 2021
The Chiesi Group is on Twitter!
17 March 2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
27 November 2020
World Prematurity Day: Chiesi is at the forefront for preterm babies
17 November 2020
Chiesi USA, Inc. announces FDA approval of Bronchitol® (mannitol) inhalation powder
02 November 2020
Regeneration 20|3, the first global meeting to launch the program is in Parma on October 15 and 16.
06 October 2020
Italy for Climate: Chiesi at the forefront for the future of Italy
01 October 2020
CHIESI JOINS THE MOVEMENT OF ITALIAN B CORP COMPANIES “UNLOCK THE CHANGE”
20 July 2020
The B Change: the Instant Book by Pharmastar is online
14 July 2020
Chiesi Group and Holostem Terapie Avanzate announce transfer of Holoclar® from the Chiesi Group to Holostem
16 June 2020
Happiness&Wellbeing: Maria Paola Chiesi at the Vatican workshop
29 May 2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease
28 May 2020
Chiesi Group and Apotex Inc. finalize agreement for acquisition of Ferriprox® (deferiprone)
13 January 2020
Chiesi Group Announces Closing of Licensing Transaction with Santhera for an orphan drug in LHON
02 August 2019
Chiesi Group signs an Option Agreement with Inhibrx for Development and Commercialization of INBRX-101 (AAT-Fc)
30 May 2019
Chiesi Group Enters into License Agreement with Santhera for a treatment for LHON
23 May 2019
Chiesi: “imprese per innovazione” award, Industry 4.0 and Sustainability Special Mentions
08 February 2019
Chiesi enters in an exclusive global license agreement with TiumBio to develop innovative molecules for respiratory diseases
09 January 2019
StartUp Health raises 31 million dollars from the Chiesi Group and a prominent group of other large pharmaceuticals companies and healthcare organizations
02 October 2018
Chiesi signs a deal with StartUp Health: first investment in the digital area
05 June 2018
Chiesi supports The Third Day exhibition, dedicated to the relationship between man and nature
17 April 2018
Global Corporate Development : opening of new offices in Boston
16 March 2018
Chiesi Digital Transformation - Digital Safari Workshop with David Orban
24 January 2018
Chiesi enters into an Exclusive ex-US Partnership with Protalix BioTherapeutics for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
20 October 2017
Chiesi certified Top Employer also for 2017
13 February 2017
Chiesi is Top Employer again!
15 February 2016
Alberto, Paolo and Andrea Chiesi winners of the “Entrepreneur of the year 2015” Award
30 November 2015
Special Mention to Holoclar at the Italian Galeno Award
26 November 2015
COPD indication for Foster pMDI
21 March 2014
Double-digit growth and internal expansion for the Chiesi Group
